Physician profile
Rory S Breidbart
NPI 1285600973
$77,232.31
in general payments reported to CMS, 2019-2025
45 companies · $683 in 2025
The $683 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $6,932 · 2021: $3,899 · 2022: $37K · 2023: $9,806 · 2024: $1,834 · 2025: $683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,470 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,425 · Travel and Lodging: $1,346 · Education: $82.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,470.04 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,425.00 |
| Travel and Lodging | $1,346.46 |
| Education | $82.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $41,319.49 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $12,083.80 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $8,398.76 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,896.19 | 2019-2024 | Cycloset |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,817.61 | 2019-2024 | Synjardy, Jardiance, Tradjenta |
| Amgen INC. | $1,056.57 | 2019-2025 | Evenity, Prolia, Tepezza |
| Xeris Pharmaceuticals, INC. | $931.88 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Astrazeneca Pharmaceuticals LP | $837.20 | 2019-2023 | Farxiga |
| Radius Health, INC. | $787.89 | 2020-2025 | Tymlos |
| Abbott Laboratories | $742.29 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amneal Pharmaceuticals LLC | $687.47 | 2019-2024 | Unithroid |
| Novo Nordisk INC | $668.34 | 2019-2025 | Wegovy |
| Abbvie INC. | $541.12 | 2019-2025 | Synthroid |
| Amarin Pharma, INC. | $518.97 | 2019-2022 | |
| Dexcom, INC. | $385.32 | 2021-2024 | Dexcom G6 Transmitter |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lifescan, INC. | $340.17 | 2019-2023 | |
| Mannkind Corporation | $241.62 | 2019-2024 | |
| Becton, Dickinson and Company | $161.49 | 2019-2022 | |
| Ascendis Pharma Endocrinology INC | $144.36 | 2025 | Yorvipath |
| Pfizer INC. | $136.44 | 2023 | |
| Intuity Medical INC | $134.73 | 2022 | |
| Novartis Pharmaceuticals Corporation | $129.40 | 2022-2024 | |
| Ibsa Pharma INC. | $128.39 | 2019-2022 | |
| Corcept Therapeutics | $108.60 | 2021-2023 | Korlym |
| Janssen Pharmaceuticals, INC | $99.63 | 2019-2022 | |
| Esperion Therapeutics, INC. | $88.03 | 2020-2024 | Nexletol |
| Alexion Pharmaceuticals, INC. | $86.16 | 2023-2024 | Strensiq |
| Insulet Corporation | $85.32 | 2019-2023 | Omnipod |
| Medtronic, INC. | $83.39 | 2021-2023 | Minimed 780g |
| Embecta Corp. | $82.54 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Horizon Therapeutics Plc | $68.77 | 2020-2023 | Tepezza |
| Tandem Diabetes Care, INC. | $63.03 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Avvisto Therapeutics, LLC | $61.89 | 2024 | Cycloset |
| Ultragenyx Pharmaceutical INC. | $51.23 | 2021-2022 | |
| Medtronic Minimed, INC. | $43.28 | 2019-2020 | |
| Azurity Pharmaceuticals, INC. | $33.38 | 2023 | Adthyza |
| Amryt Pharma Holdings LTD | $31.14 | 2022 | |
| Vistapharm, INC. | $25.47 | 2021 | |
| Beta Bionics, INC. | $22.93 | 2024 | Ilet Bionic Pancreas |
| Shire North American Group INC | $20.42 | 2019 | |
| Echosens North America, INC. | $20.00 | 2019 | |
| Cequr Corporation | $18.46 | 2023 | Cequr Simplicity |
| Alfasigma USA, INC. | $16.97 | 2021 | |
| Zealand Pharma US, INC. | $16.39 | 2022 | |
| Recordati_rare_diseases_inc. | $15.78 | 2025 | Isturisa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rory Breidbart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.